ArticleProceedings of the National Academy of Sciences of the United States of America2019
Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare
Open access · bronzeAbstract readCase Reports
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- A comprehensive clinical trajectory ofTranslational lung cancer research · 2026Article
- Landscape of cancer associated EpCAM mutations: molecular modeling, predictive insights and impact on patient survival.BMC cancer · 2025Article
- City scale related to epidermal growth factor receptor mutations status in Chinese non-small cell lung cancer.Discover oncology · 2025Article
- A molecular dynamics protocol for rapid prediction of EGFR overactivation and its application to the rare mutations S768I, S768N, D761N.Computational and structural biotechnology journal · 2025Article
- [EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Future direction of total neoadjuvant therapy for locally advanced rectal cancer.Nature reviews. Gastroenterology & hepatology · 2024Review
- D3EGFR: a webserver for deep learning-guided drug sensitivity prediction and drug response information retrieval for EGFR mutation-driven lung cancer.Briefings in bioinformatics · 2024Article
- Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies.Biomedicines · 2024Review
- Evaluating the ability of end-point methods to predict the binding affinity tendency of protein kinase inhibitors.RSC advances · 2023Article
- Structure-Guided Strategies of Targeted Therapies for Patients withBiomolecules · 2023Review
- Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis.Cancer research · 2022Article
- Predicting the mutation effects of protein-ligand interactions via end-point binding free energy calculations: strategies and analyses.Journal of cheminformatics · 2022Article
- Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.Cancer discovery · 2022Article
- A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.Translational lung cancer research · 2022Article
- Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2022Review
- Remarkable Differences in Calcification between the Primary Tumor and Metastatic Lymph Nodes in a Patient with ALK-Positive Non-Small-Cell Lung Cancer.Case reports in pulmonology · 2022Article
- Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.NPJ precision oncology · 2021Article
- TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.Cancer discovery · 2021Article
- Identification of Novel Alectinib-ResistantOncoTargets and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 6 institutions in 2 countries.
Shinnosuke IkemuraDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Hiroyuki YasudaDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan; hiroyukiyasuda@a8.keio.jp ktsuchih@east.ncc.go.jp.
Shingo MatsumotoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577 Chiba, Japan.
Mayumi KamadaGraduate School of Medicine, Kyoto University, Shogoin Sakyo-ku, 606-8507 Kyoto, Japan.
Junko HamamotoDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Keita MasuzawaDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Keigo KobayashiDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Tadashi ManabeDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Daisuke AraiDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Ichiro NakachiDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Ichiro KawadaDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Kota IshiokaDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Morio NakamuraTokyo Saiseikai Central Hospital, Minato-ku, 108-0073 Tokyo, Japan.
Ho NamkoongDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Katsuhiko NaokiKeio Cancer Center, Keio University School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Fumie OnoGraduate School of Medicine, Kyoto University, Shogoin Sakyo-ku, 606-8507 Kyoto, Japan.
Mitsugu ArakiGraduate School of Medicine, Kyoto University, Shogoin Sakyo-ku, 606-8507 Kyoto, Japan.
Ryo KanadaCompass to Healthy Life Research Complex Program, RIKEN, Kobe, 650-0047 Hyogo, Japan.
Biao MaResearch and Development Group for In Silico Drug Discovery, Pro-Cluster Kobe, Foundation for Biomedical Research and Innovation, Kobe, 650-0047 Hyogo, Japan.
Yuichiro HayashiDepartment of Pathology, Keio University School of Medicine, 160-8582 Tokyo, Japan.
Sachiyo MimakiDivision of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, 277-8577 Chiba, Japan.
Kiyotaka YohDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577 Chiba, Japan.
Susumu S KobayashiDivision of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, 277-8577 Chiba, Japan.
Takashi KohnoDivision of Genome Biology, National Cancer Center Research Institute, 104-0045 Tokyo, Japan.
Yasushi OkunoGraduate School of Medicine, Kyoto University, Shogoin Sakyo-ku, 606-8507 Kyoto, Japan.
Koichi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577 Chiba, Japan.
Katsuya TsuchiharaDivision of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, 277-8577 Chiba, Japan; hiroyukiyasuda@a8.keio.jp ktsuchih@east.ncc.go.jp.
Kenzo SoejimaDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, 160-8582 Tokyo, Japan.
Keio University · JPChiba Cancer Center · JPKyoto University · JPNational Cancer Center Hospital East · JPSaiseikai Central Hospital · JPFoundation for Biomedical Research and Innovation · JP
Funding
Overcoming resistance to tyrosine kinase inhibitors in lung cancerR01CA169259 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KOBAYASHI, SUSUMU · 2013 to 2018
$1.8MNCI NIH HHS R01 CA169259
Abstract
Next generation sequencing (NGS)-based tumor profiling identified an overwhelming number of uncharacterized somatic mutations, also known as variants of unknown significance (VUS). The therapeutic significance of
Indexed as
Genes, erbB-1AcrylamidesAdenocarcinomaAniline CompoundsCarcinoma, Non-Small-Cell LungHumansIndolesLung NeoplasmsMiddle AgedMolecular Dynamics SimulationMutationPharmacogenomic TestingProspective StudiesProtein-Tyrosine KinasesPyrimidinesAcrylamidesAniline CompoundsIndolesosimertinibProtein-Tyrosine KinasesPyrimidinesin silico prediction modelmutation diversitynonsmall cell lung cancerosimertinibrare EGFR mutation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.